Gamma-aminobutyric acid receptor subunit alpha-6
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-6 as ChEMBL target CHEMBL2579, mapped to UniProt Q16445. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Gamma-aminobutyric acid receptor subunit alpha-6 matters
Gamma-aminobutyric acid receptor subunit alpha-6 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-6 (UniProt Q16445); the current evidence base includes 1 approved drug, 23 compounds, and 5 assays, with lead potency reaching pChEMBL 7.2.
Gamma-aminobutyric acid receptor subunit alpha-6 Sequence length is 453 aa.
Review this target as Gamma-aminobutyric acid receptor subunit alpha-6, mapped to UniProt Q16445. Sequence length is 453 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 23 compounds, and 5 assays for this target. The dominant activity type is KI. CHEMBL45198 is the current potency anchor at pChEMBL 7.2.
Use CHEMBL45198 as the tractability anchor when discussing potency (pChEMBL 7.2).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-6 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q16445, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL45198
|
7.2 | Ki | — |
|
|
No preferred name
CHEMBL5275690
|
7.1 | Ki | — |
|
|
No preferred name
CHEMBL5290579
|
6.9 | Ki | — |
|
|
No preferred name
CHEMBL407
|
6.8 | Ki | Approved |
|
|
No preferred name
CHEMBL5280240
|
6.3 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FLUMAZENIL
CHEMBL407
|
1991 |